Abstract:As seen in this CME online activity (available at http://courses.elseviercme.com/694), idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrotic lung disease of unknown cause that is associated with substantial health-care utilization and high rates of mortality. The clinical symptoms of IPF are nonspecific and overlap with many pulmonary and cardiac diseases making differential diagnosis challenging. The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines strongly recommend a multidisciplinary approach to the diagnosis of interstitial lung diseases; however, there are several limitations to the feasibility of this approach in clinical practice. Although early diagnosis is relevant to any chronic, progressive, and irreversible disorder, it is crucially important that effective treatments for IPF are prescribed without delay. A window of opportunity may exist during which time treatment can have optimal outcomes. Evidence on the clinical management of IPF is rapidly evolving, and key updates were made to the most recent ATS/ERS/JRS/ALAT guidelines. The widely used combination of prednisone, azathioprine, and N-acetylcysteine has now been associated with increased risk of hospitalization and death compared with placebo in patients with IPF. These treatments and others for IPF have been mostly supportive, but recently pirfenidone and nintedanib have demonstrated efficacy in reducing functional decline and disease progression in IPF. A pooled analysis of three phase 3 studies of pirfenidone found a significant 48% reduction in all-cause mortality, and a pooled analysis of a phase 2 and two phase 3 studies of nintedanib found a significant 43% reduction in on-treatment mortality. As patient exposure to these two new drugs increases, data continue to emerge on how and when to use these medications and on how to manage their side effects. Finally, several medications targeting the fibrotic pathobiology of IPF are currently in development. Given the limited treatment options for IPF, enrollment in a clinical trial may be the best chance to delay or prevent progression of IPF. This CME-certified expert video roundtable from CHEST reviews the ATS/ERS/JRS/ALAT guidelines with a specific focus on accurate and timely diagnosis of IPF and the latest data on the treatment of IPF.

Idiopathic Pulmonary Fibrosis: Diagnosis and Prognostic Evaluation

Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes

Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions

Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management

[Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances]

Idiopathic Pulmonary Fibrosis (IPF): An Overview

Prospects for Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis and occupational risk factors

Idiopathic Pulmonary Fibrosis: Review of Current Knowledge

Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors

Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review

[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]

Idiopathic pulmonary fibrosis: state of the art for 2023

Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers

Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment

Retrospective Study on Prognostic Factors of Idiopathic Pulmonary Fibrosis

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis